Zhengda Qing "Dabiga group ester capsules" first imitation approved as through the consistency evaluation.

On March 18, Zhengda Qing according to the new 4 categories of declared Dabiga group ester capsules approved by the State Drug Administration, as the same through the consistency evaluation, as the first in the country.
dabiga group ester capsules, a new generation of non-vitamin K antagonists are oral anticoagulants used to prevent stroke and systemic embolism in patients with non-valve atrial fibrillation.
this is the first oral anticoagulant to obtain long-term indications since Huafalin was approved for the market, and its original research manufacturer is Bollinger Ingham.
2010/10/19 Dabbyga group ester capsules are approved by the FDA for listing, the product name: Pradaxa, 2013/1/30 approved by NMPA to enter the Chinese market, and included in the 2019 new health insurance catalog.
sales of Darbiga ghetto capsules continued to grow after the market, reaching EUR 1,486 million in 2018.
at present, there are a number of domestic pharmaceutical companies for the development of Darbiga group ester capsules, in addition to Zhengda Qingtou to the first imitation, Chengdu Bite, Jiangsu Hausen, Chengdu Yuandong 3 enterprises are also applying for listing.
2019, 14 generic drugs were approved, making them the biggest winners of the 2019 generics.
in February this year, there are large-hot varieties of inhalation with budined mixed suspension first approved, it can be seen that Zhengda Qing in the field of generic drugs is still gradually expanding advantages.
.